You are here

A Trial Of SU14813 In Patients With Advanced Solid Malignancies

Last updated on March 11, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Hamburg, , 20246 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms, Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with a histologically proven advanced solid malignancy for which no
recognized therapy was available or for which standard therapy had failed

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy
or an investigational agent within 4 weeks before the start of study treatment

- Subjects had to have recovered from all prior treatment toxicities, except alopecia,
and from any major surgery.

NCT00982267
Pfizer
Completed
A Trial Of SU14813 In Patients With Advanced Solid Malignancies

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Locally Advanced or Metastatic Solid Tumors, BRCA 1 Genes
NCT03565991
All Genders
18+
Years
Multiple Sites
Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma
NCT03709680
All Genders
2+
Years
Multiple Sites
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Advanced Solid Tumors, Metastatic Solid Tumors
NCT03854227
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now